Compare PRGS & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGS | SPTX |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1995 | 2026 |
| Metric | PRGS | SPTX |
|---|---|---|
| Price | $43.50 | $24.81 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $49.50 | N/A |
| AVG Volume (30 Days) | ★ 402.4K | 112.4K |
| Earning Date | 03-30-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.79 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $397,572,000.00 | N/A |
| Revenue This Year | $3.70 | N/A |
| Revenue Next Year | $1.08 | N/A |
| P/E Ratio | $42.07 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.82 | $17.59 |
| 52 Week High | $47.37 | $28.38 |
| Indicator | PRGS | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 56.51 |
| Support Level | $42.22 | $23.46 |
| Resistance Level | $43.96 | $28.38 |
| Average True Range (ATR) | 1.45 | 2.07 |
| MACD | -0.16 | -0.17 |
| Stochastic Oscillator | 30.84 | 33.53 |
Progress Software Corp provides software products that enable customers to develop, deploy, and manage AI-powered applications and digital experiences. The Company operates across North America, Latin America, Europe, the Middle East and Africa (EMEA), and Asia Pacific through subsidiaries and distributors, generating a majority of its revenue from the United States. Its product portfolio includes Progress Agentic RAG, Automate MFT, Chef, Corticon, DataDirect, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, and WhatsUp Gold, offering solutions for application development, data connectivity, DevOps automation, managed file transfer, network security, and digital experience. It generates maximum revenue from the United States.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.